RecruitingPhase 2NCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Studying Adenocarcinoma of the cervix uteri

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Fluorouracil (5-FU)(drug)
Enrollment: 450 target
Eligibility: 18-130 years · All sexes
Timeline: 2020 – 2027

Study locations (30)

Research Site, Santa Monica, California, United States
Research Site, Westwood, Kansas, United States
Research Site, Baltimore, Maryland, United States
Research Site, Boston, Massachusetts, United States
Research Site, Ann Arbor, Michigan, United States
Research Site, New York, New York, United States
Research Site, Durham, North Carolina, United States
Research Site, Houston, Texas, United States
Research Site, Fairfax, Virginia, United States
Research Site, Florianópolis, Brazil
Research Site, Londrina, Brazil
Research Site, Natal, Brazil
Research Site, Porto Alegre, Brazil
Research Site, Ribeirão Preto, Brazil
Research Site, Rio de Janeiro, Brazil
+15 more locations on ClinicalTrials.gov

Collaborators

Daiichi Sankyo

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04379596 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the cervix uteri →

← Back to all trials